CO2017005391A2 - Composiciones de antibiótico - Google Patents

Composiciones de antibiótico

Info

Publication number
CO2017005391A2
CO2017005391A2 CONC2017/0005391A CO2017005391A CO2017005391A2 CO 2017005391 A2 CO2017005391 A2 CO 2017005391A2 CO 2017005391 A CO2017005391 A CO 2017005391A CO 2017005391 A2 CO2017005391 A2 CO 2017005391A2
Authority
CO
Colombia
Prior art keywords
acetyl
solutions
amino acid
vancomycin
alanine
Prior art date
Application number
CONC2017/0005391A
Other languages
English (en)
Inventor
Ivona Jasprica
Sabina Keser
Katarina Pindric
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017005391(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of CO2017005391A2 publication Critical patent/CO2017005391A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Resumen de la Descripción Se proveen soluciones que comprenden un antibiótico glicopéptico, por ejemplo, Vancomicina, y un aminoácido o derivado de aminoácido tal como N-acetil-Glicina o N-acetil-D-Alanina. Estas soluciones son estables o estabilizadas por periodos de tiempo largos en condiciones de uso normal y almacenamiento, y pueden ser formuladas como soluciones farmacéuticas para usarse en sujetos. También se proveen métodos de fabricación y uso de estas soluciones, como lo son métodos de estabilización de un antibiótico glicopéptido, por ejemplo, Vancomicina, usando aminoácidos o derivados de aminoácidos tales como N-acetil-Glicina o N-acetil-D-Alanina.
CONC2017/0005391A 2014-11-06 2017-05-26 Composiciones de antibiótico CO2017005391A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30
PCT/EP2015/075918 WO2016071495A1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Publications (1)

Publication Number Publication Date
CO2017005391A2 true CO2017005391A2 (es) 2017-10-31

Family

ID=54478023

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005391A CO2017005391A2 (es) 2014-11-06 2017-05-26 Composiciones de antibiótico

Country Status (30)

Country Link
US (7) US10188697B2 (es)
EP (4) EP3542812B1 (es)
JP (2) JP6797795B2 (es)
KR (2) KR102603756B1 (es)
CN (1) CN107073072B (es)
AU (1) AU2015341763B2 (es)
BR (1) BR112017009405B1 (es)
CA (1) CA2964524A1 (es)
CL (1) CL2017001139A1 (es)
CO (1) CO2017005391A2 (es)
CR (1) CR20170234A (es)
CY (2) CY1122960T1 (es)
DK (2) DK3542812T3 (es)
EA (1) EA035368B1 (es)
ES (2) ES2852550T3 (es)
HR (2) HRP20200101T1 (es)
HU (2) HUE053347T2 (es)
IL (1) IL252120B (es)
MX (1) MX2017005749A (es)
NZ (1) NZ731955A (es)
PH (1) PH12017500720A1 (es)
PL (2) PL3542812T3 (es)
PT (2) PT3542812T (es)
RS (2) RS61418B1 (es)
SA (1) SA517381446B1 (es)
SG (1) SG11201703568WA (es)
SI (2) SI3215173T1 (es)
TN (1) TN2017000182A1 (es)
WO (1) WO2016071495A1 (es)
ZA (1) ZA201702767B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170234A (es) 2014-11-06 2018-01-15 Xellia Pharmaceuticals Aps Composiciones de antibiótico
US20190000789A1 (en) * 2015-12-24 2019-01-03 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
WO2017194385A1 (en) * 2016-05-09 2017-11-16 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
EP3544616A4 (en) * 2016-11-23 2020-12-09 Gufic Biosciences Limited LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
CA3132923A1 (en) 2019-03-08 2020-09-17 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
US20220133844A1 (en) * 2020-10-30 2022-05-05 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
PE40996A1 (es) 1994-01-28 1996-10-14 Lilly Co Eli Derivado de antibiotico de glucopeptido
AU1407197A (en) 1995-12-01 1997-06-19 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
WO2003082273A1 (en) * 2002-03-26 2003-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
CN1826129A (zh) * 2002-07-09 2006-08-30 尖端医疗有限公司 与异亮氨酸硼脯氨酸化合物相关的方法和组合物
US20050130909A1 (en) 2002-11-18 2005-06-16 Luigi Colombo Dalbavancin compositions for treatment of bacterial infections
ES2482700T3 (es) 2005-02-14 2014-08-04 Venus Remedies Limited Terapia de combinación parenteral para enfermedades infecciosas causadas por una bacteria resistente a los medicamentos
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) * 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
EP2709646A4 (en) * 2011-05-19 2015-05-13 Savara Inc DRY POWDER VANCOMYCIN COMPOSITIONS AND RELATED METHODS
WO2014026052A1 (en) 2012-08-08 2014-02-13 Vanderbilt University Composition with biofilm dispersal agents
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
AU2015229069A1 (en) 2014-03-14 2016-11-03 CutisPharma,Inc. Composition and method for vancomycin oral liquid
CR20170234A (es) * 2014-11-06 2018-01-15 Xellia Pharmaceuticals Aps Composiciones de antibiótico
WO2017194385A1 (en) 2016-05-09 2017-11-16 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
US20220133844A1 (en) 2020-10-30 2022-05-05 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
PT3542812T (pt) 2021-04-20
HUE049857T2 (hu) 2020-10-28
SI3215173T1 (sl) 2020-03-31
MX2017005749A (es) 2018-01-11
EP4147710A1 (en) 2023-03-15
EP3215173A1 (en) 2017-09-13
EP3542812B1 (en) 2021-01-13
ES2769849T3 (es) 2020-06-29
PH12017500720A1 (en) 2017-10-09
US20180133286A1 (en) 2018-05-17
US11517609B2 (en) 2022-12-06
HRP20200101T1 (hr) 2020-04-03
SG11201703568WA (en) 2017-05-30
CA2964524A1 (en) 2016-05-12
ZA201702767B (en) 2018-12-19
US10188697B2 (en) 2019-01-29
SI3542812T1 (sl) 2021-04-30
SA517381446B1 (ar) 2020-09-21
EA035368B1 (ru) 2020-06-03
HUE053347T2 (hu) 2021-06-28
HRP20210342T1 (hr) 2021-04-30
HRP20210342T8 (hr) 2022-01-21
BR112017009405A2 (pt) 2018-01-02
JP2017533218A (ja) 2017-11-09
EP3542812A1 (en) 2019-09-25
BR112017009405B1 (pt) 2024-02-06
IL252120A0 (en) 2017-07-31
US20230158101A1 (en) 2023-05-25
PT3215173T (pt) 2020-04-03
US20170348385A1 (en) 2017-12-07
PL3542812T3 (pl) 2021-07-12
EP3215173B1 (en) 2020-01-01
US20200069768A1 (en) 2020-03-05
US20210220433A1 (en) 2021-07-22
US11000567B2 (en) 2021-05-11
EP3834837A1 (en) 2021-06-16
CY1124011T1 (el) 2022-05-27
AU2015341763B2 (en) 2019-01-17
CN107073072A (zh) 2017-08-18
US10849956B2 (en) 2020-12-01
CN107073072B (zh) 2021-06-18
EP3215173B8 (en) 2020-03-11
CL2017001139A1 (es) 2017-12-01
KR20230096142A (ko) 2023-06-29
EA201790997A1 (ru) 2017-09-29
IL252120B (en) 2020-07-30
US20220354927A1 (en) 2022-11-10
US20190160142A1 (en) 2019-05-30
AU2015341763A1 (en) 2017-06-08
RS61418B1 (sr) 2021-03-31
CY1122960T1 (el) 2021-10-29
PL3215173T3 (pl) 2020-05-18
KR102603756B1 (ko) 2023-11-16
JP7032488B2 (ja) 2022-03-08
JP2020183424A (ja) 2020-11-12
DK3542812T3 (da) 2021-04-12
CR20170234A (es) 2018-01-15
TN2017000182A1 (en) 2018-10-19
KR20170078830A (ko) 2017-07-07
JP6797795B2 (ja) 2020-12-09
DK3215173T3 (da) 2020-03-23
RS59851B1 (sr) 2020-02-28
ES2852550T3 (es) 2021-09-13
US10039804B2 (en) 2018-08-07
WO2016071495A1 (en) 2016-05-12
NZ731955A (en) 2023-07-28
US11628200B2 (en) 2023-04-18

Similar Documents

Publication Publication Date Title
CO2017005391A2 (es) Composiciones de antibiótico
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
HUE039931T2 (hu) Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények
UY35500A (es) Indazoles sustituidos con heteroarilo
UY35351A (es) Formulaciones acuosas estables de adalimumab
EA201591809A1 (ru) Стабилизированный состав витамина d с модифицированным высвобождением и способ его введения
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
MX2016005395A (es) Formulacion estable de insulina glulisina.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
TW201613557A (en) Stable aqueous recombinant protein formulations
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
UY34322A (es) ?compuestos reguladores del crecimiento vegetal, método para su aplicación y uso de dichos compuestos?.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
BR112017027721A2 (pt) formulação de alta concentração
MX2018001219A (es) Composicion farmaceutica con estabilidad de almacenamiento mejorada y metodo para prepararla.
EP3135299A4 (en) Active ingredient (i) containing composition and method for preparing same